Gilead AIDS Drug Antitrust Case To Get Appeal

By Eric Kroh (July 12, 2016, 3:15 PM EDT) -- The AIDS Healthcare Foundation will appeal a California federal judge's decision last week that dismissed the group's antitrust and patent invalidation claims against Gilead Sciences Inc. over HIV treatments, the foundation said on Monday.

The organization said U.S. District Judge William Alsup's order dismissing the case suggested that it is ripe for reconsideration by higher courts. The foundation contends that Gilead gamed the U.S. Food and Drug Administration regulatory process to protect its market position for so-called prodrugs of tenofovir alafenamide fumarate, an HIV and AIDS drug also referred to as TAF. The group alleged Sherman Act, Cartwright Act and state...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!